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REGULATING MAMMOGRAMS
Breast cancer is perhaps the most feared disease for women. Although other
illnesses might be more deadly from a statistic point of view, women seem
more concerned about breast cancer (in fact, breast cancer is the second leading
cause of cancer mortality in women). This fear has resulted in an enormous
preoccupation with the disease, and in particular, with diagnosing and treating
the cancer. And [s]ince currently there is no cure for breast cancer or method to
prevent it from occurring, the key to saving women's lives is the early detection
of the disease, when treatment is the most eective and survival rates are best.1
Mammography is widely used as a cancer detection device; unfortunately, it is
often misused or performed inadequately. The need for proper supervision and
regulation is of a concern to every woman.
I. BREAST CANCER AND MAMMOGRAPHY
In 1997 approximately 180,00 new cases of breast cancer were detected among
women in the United States, and around 45,000 women died from the disease.2
Breast cancer develops in stages; the ability to detect cancer in those rst stages
is vitally important to a woman's prognosis
Nih Recommendations on Mammograms: 1-learings Belore the Subcomm.
on Labor, Health and Human Services
and Education of the Senate Comm. on Appropriations, in 1997 WL 49424
(1997) (statement of Susan J. Blumenthal, Deputy Asst. Sec. for Health, Asst.
Surgeon General, U.S. Public Health Service) [hereinafter Hearings 1.
2 See American Cancer Society. Breast Cancer information (as of Jan. 23,
1998), available in
http://www.cancer.org/benIbrstats. html.
1and tbture. Mammography is one of the most important detection tools
currently available to
women and doctors. In fact, many physicians and experts have agreed that
mammography is the best method of detecting breast cancer at its earliest
stages.3
4
There are two types of mammograms. A screening mammogram (which is
the type
discussed in this paper) is an x-ray of the breast used to detect breast cancer
in women who have
no signs of cancer. It usually involves two x-rays of each breast. Diagnostic
mammograms, by
contrast, are used to diagnose unusual breast changes and used to evalu-
ate abnormalities detected on a screening mammogram. About 23.5 million
mammograms were performed in the U.S. in
1994, costing approximately $2.5 billion.5
Mammography is a particularly complex examination. It is one of the hard-
est
radiological examinations to do properly because the quality of the image is
more dependent on
accurate equipment performance and correct processing of lm than other
types of x-ray exams.,,6
'~ See Judith Willis, Why Women Don '1 (Jet Mammograms (And Why
They Should), FDA CON5U~R, May 1987, at
5. Mammography can detect a breast tumor as much as two years
before lump can be felt. John Schwartz, FDA
Seeks to Improve Quality of Mammography; Rules Set Mandatory Verica-
tion System, WASHINGTON PosT, Dec. 2,
1993, at A3. At the time of the act's enactment, the National Cancer Insti-
tute estimated that annual screening of
women over 50 can reduce breast cancer deaths by about a third. See Leslie
Miller, Mammogram Centers Must
Meet Standards, USA TODAY, Sept. 30, 1994, at D6 (Life section).
See generally, National Cancer Institute, Cancer Facts: Detection (as of Jan.
23, 1998), available in http://cancernet.nci. nih.gov/clinpdq/detectioniScreening
Mammograms html.
 Rich Weiss, Mammography Centers Flunking Inspections, WASH-
INGTON POST, Nov. 28, 1995, at 5 (Health section).
6
HHS Issues Mammogram Guidelines That Seek Better Tests, Faster Results,
WASHINGTON POST, Oct. 20, 1994,
at AS.
2Robert Schmidt, the radiologist in charge of breast imaging at the University
of Chicago Hospital,
estimates that probably more than ten percent and as high as thirty percent
of a mammogram's
7
ndings may be wrong - due to human error.
Because mammography is so important, the federal government has felt an
obligation to ensure as many women have one as possible. Despite the fact that
the exam is vital, many women do not have the exam. The National Cancer
institute estimates that only half of the women over 50 (the group at greatest
risk of contracting cancer) receive mammograms on a regular basis.8
Ii. DEVICE APPROVAL AND REGULATION
There are two primary areas in which mammography has been heavily regulated
by the FDA. One such area is the FDA's regulation of radiological/mammography
devices under the medical device program of its Center for Devices and Radio-
logical Health.9
Until recently, the regulation of mammography as a medical device received
little attention. Because the machines used are the same as the traditional x-ray
machines that are used in a wide variety of medical settings, regulation of the
actual equipment seemed to be an afterthought. Yet, regular mammography is
not full-proof It misses 15-20% of cancers and 80%
Michael Unger, Digital Mammography Lifts Ilopes]br Better Detection, NEWS-
DAY, Dec. 19, 1995, at B28. S Sandy Rovner, Standards Set/br Mammograms,
WASHINGTON POST, Nov. 15. 1995, at 18 (Health section).
~ This section primarily deals with diagnostic devices sold to and
used by physicians. There is also a new device on the market, which just recently
received FDA approval, which helps a woman perform breast self examinations.
The Sensor Pad (designed to increase sensation during breast self examinations)
can be sold over the counter {originally, in 1995, it was approved by the FDA as
a prescription product. See generally, Bruce Ingersoll, FDA Clears Device for
Breast Exams Alter Long Wait, WALl. STREET JOURNAL, Nov. 18, 1997,
at B16.
3of the lesions found by mammography turn out to be benign. '~ Thus, new
technologies and methods are needed to enhance cancer detection. Advances in
science and technology have created more complex and novel machines. These
new machines must be approved for mammography use by the FDA before they
can be marketed as mammography equipment. And the FDA does enforce its
rules. In 1997, for example, Biopsys Medical Inc. was forced to stop marketing
its product as a cancer detection device after receiving a warning letter from
the
FDA.
In fact, these machines are not truly new. Some employ technology that has
been utilized in other medical settings. Thus, these devices have already been
approved for other uses by the FDA. Yet, equipment that is marketed specically
as a mammography device must rst be approved by the agency. However,
this does not preclude manufacturers from creating these devices. Furthermore,
many physicians use radiological equipment to perform a mammogram that was
originally designed for another use. What we regulate is the marketing of the
product by the manufacturer. We don't regulate how doctors use the product
once it's out on the market said
12
an FDA spokeswoman. This practice is similar to doctors prescribing drugs
that were originally designed for one use to treat another completely dierent
ailment, even though the manufacturer
never marketed the drug for that purpose. Thus, radiological devices do not
necessarily need to
10Hearings, supra note 1.
See Barbara Marsh, l3iopsys Medical Agrees to Alter Promotion of Its Main
Product, Los ANGELES TIMEs, Feb. 25, 1997, at D12.
12
Dolores Kong, Better Imaging SecAs to Limit Breast Biopsies, BOSTON
GLOBE, Apr. 22, 1996, at 25.
4be approved as mammography devices by the FDA if the manufacturer has
no intention of marketing its devices as mammography devices.
However, some manufacturers do want to be able to market their devices to
more physicians and hospitals for use as a mammographic machine. As men-
tioned above, these new devices rst need to be approved by the FDA. Approval
of such devices has recently received much attention. The new advances are cel-
ebrated by physicians and patients alike because they improve the quality of the
image taken. This improvement in quality can both save lives (by detecting can-
cer earlier) and money (by eliminating costly further tests when a mammogram
picture is unclear or inconclusive). And of course, manufacturers are asking for
approval to be able to market the device to a wider range of customers.
Ultrasound is being used as a possible backup to mammography. In this
procedure, the machine builds an image of the breast by sending high fre-
quency sound waves through the body.'3 The FDA approved the application
of Advanced Technology Laboratories (ATL) to market and use ultrasound as
a breast cancer diagnostic tool.'4 In its 18 month study of 1,000 women, ATL
found that using ultrasound to supplement regular mammograms reduced the
number of biopsies
13 See John Schwartz, Feds OK Ultrasound Test of Breast Lumps, PORT-
LAND OREGoNIAN, Apr. 13, 1996, at Al. '~ Id. ATL was the rst company
to actually submit clinical data to show the eectiveness and safety of the
procedure, in order to market the device as a breast cancer diagnostic tool.
See Kong, supra note 12. Although most responses have been positive, ultra-
sound has its critics. Daniel Kopans, director of the breast imaging division
of the Massachusetts General Hospital, simply stated that the approval of the
ultrasound machine was a great marketing ploy. Kong. supra note 12. Other
doctors are more optimistic about magnetic resonance imaging and digital mam-
mography. See id
5by a third.15 ATL's machines give an image sharp enough to allow doctors
to distinguish between benign and cancerous solid lumps.'6 The device could
also reduce the rate of false positives from 75% to 4100.17 ATL was forced to
seek pre-market approval, rather than conform to a less stringent standard for
existing technology.'8
Magnetic resonance imaging creates images from signals generated by the
excitation of nuclear particles in a magnetic eld.19 MIRI has emerged as an
exciting development because it oers an important advantage: higher deni-
tion images without radiation.20 It also is more successful in taking images of
younger women, whose breast tissue is usually too thick to produce a readable
mammogram. Although the device received FDA approval in 1996, the pro-
cedure currently is extremely costly.21 Advanced Mammography Systems, Inc.
is currently selling this device. However, due to its high cost, the FDA will
only allow the company to market the device for diagnosis, not for screening,
purposes.22
15 See Warren King, Study: Ultrasound Boosts Accuracy of Mammogram,
NEW ORu~ANs TIMES-Picayune, Feb. 4,
1996, at AIO. The elimination of unnecessary biopsies is important. In
biopsies, a portion of the breast is removed
and analyzed. Although a biopsy is the only 100% certain way to determine
the status of an abnormality in the
breast (see Kong, supra note 12), many biopsies are performed needlessly.
About 70-80% of tissue from these biopsies turns out to be benign. Biopsies are
also painful and costly for the patient. See generally, King, supra. 16 Schwartz,
supra note 13.
~ Id.
18Kong, ,supra.note 12.
19Hearings, supra note I.
20
Eric Convey, Device to Diagnose Breast Cancer OK 'd, BOSTON HERAI.D,
Mar. 1, 1996, at 20.
21 See generally, id
22 See id.
6Digital mammography is perhaps the most advanced improvement to be de-
veloped. Prior to 1995, full breast digital imaging was expensive and inadequate.
However, the machines have been rened.23 The new machines use no lm. They
take an image of the full breast and display that on a high denition computer
screen. That image can then be saved or transmitted elsewhere is necessary.
Digital enhancement of the image allows a physician to detect abnormalities
that are normally dicult to recognize on a lm screen.24 Newer technology
has also enabled manufacturers to drop the price of this type of machine. Full
breast digital imaging machines were being tested in Northeast areas. A New
York company had, as of December 1997, applied for FDA approval to begin
marketing the rst full-breast digital imaging system.25
Finally, positron-emission tomography that produces molecular images is an
experimental method that seeks to distinguish cancer cells from normal tissue
based on dierences in their metabolism and other characteristics.26
Currently, many of these new mammography machines are being studied
or marketed. However, truly accurate and long term studies will ultimately
determine the safety and
23 See generally, Michael Unger, Digital Mammography Li/Is hopes for Bet-
ter Detection, NEWSDAY, Dec. 19,
1995, at B28.
24 See id
25 See Michael Unger, led Approval Sought/br Digital lmaging, NEWSDAY,
Dec. 3, 1997, at A60. In fact, the
FDA has delineated guidelines for such manufacturers seeking marketing
clearance. See Information for Manufacturers Seeking Marketing Clearance of
Digital Mammography Systems (updated Aug. 13, 1996), available in http://www.fda.gov/cdrh/ode/djgmammo.html.
In general, manufacturers must have a system of quality assurance tests in place
to ensure that the system is operating properly. See id
26 Susan Okie, More Women are Getting Mammograms, WASHINGTON
POST, Jan. 21, 1997, at 7 (Health section).
7eectiveness of these methods. In fact, one study will compare various breast
imaging devices over a period of ve years.27
III. PERFORMANCE REGULATION
The FDA has also regulated mammography by attempting to regulate how
well mammograms are performed - by regulating the facilities, doctors, and
equipment that are utilized when mammograms are given.
Although recent events and laws have focused attention on the FDA's role in
regulating mammograms, the FDA's involvement spans more than just a decade
or two. The agency rst become interested in mammography in 1974, after a re-
port came out measuring the radiation exposures to women from mammography
techniques.28 Thus, the following year the Center for Devices and Radiological
Health began the Breast exposure Nationwide Trends program, its objective be-
ing to locate facilities giving excessively high radiation exposures and to assist
them in reducing the exposures.29 Due to the government's and the manufac-
turers' involvement, radiation exposure decreased. Attention then focused on
the quality of the mammogram's
27 See Helen Bond, New Technology Makes Breast Cancer Easier to Find,
DALLAS MORNING NEws, Oct. 27, 1997,
at C3.
28 The report was done by Henry Bicehouse, a Pennsylvania state inspector.
The report showed that in a few cases,
the level of radiation the woman was exposed to was extremely high. See
Marian Segel, Mammography Facilities Must Meet Quality Standards, 28 FDA
CoNSUMER 8 (1994).
29 ld.
8images. In 1985, the FDA began using a new phantom30 to conduct a nation-
wide mammographic survey. This study demonstrated the poor quality of some
mammograms, due more to human error than to inaccurate mammographic
devices.31 The problem was handed over to the American College of Radiol-
ogy (ACR). This prompted ACR to establish its own voluntary accreditation
program. At the time, the federal government was also establishing criteria for
facilities that wanted to receive Medicare reimbursement. In developing a new
system, the government in a sense merged these two programs to create the
governing law in place today.
Before the early I 990s, FDA regulation consisted primarily of medical device
regulation. Yet there remained a problem - human error. All too often, mam-
mograms do not reect their pull [sic] potential as preventative tools because
equipment, physicist, technologist, or radiologist 'error(s)' compromise quality
and accuracy.,'32 Thus, at the urging of Senator Barbara Mikulski and Rep-
resentative John Dingell, in 1992 Congress passed a law that would allow the
FDA to regulate mammography facilities. The regulations created the rst such
mandatory national program,.33 In general, the act, named the Mammography
Quality Standards Act34 (MQSA),
30 A phantom is a plastic device embedded with objects of varying materials
and size that is used to evaluate image quality. The device is x-rayed as though
it were a breast, and the image score is determined by the number of objects
picked up by the x-ray lm. Id.
31 See id
32 Suzanne V. Cocea, Who's Monitoring the Quality of Mammograms? The
Mammography Quality Standards Act
of 1992 ( 7ould Finally Provide theAsnwer, 19 AM. J.L. & MED. 313, 315
(1993).
33
John Schwartz, FDA Seeks to Improve Quality a/Mammography; Rules Set
Mandatory Verication System,
WASHINGTON POST, Dec. 2, 1993, at A3. Mammogaphy quality has
also been reguklated at the provate and sta5e level. See Cocca, supra note 32,
at 316.
9creates quality control standards and a certication system for most of the
nation's mammography facilities. The Act's enactment made mammography
the only diagnostic imaging test to be
federally regulated for quality.35 The nal rules were announced at the end
of 1997 to much publicity.36
The implementation of MQSA is delineated into two main areas: accredita-
tion and quality
37
standards/certication. The rst part of this regulation discusses the pro-
cedures whereby an entity can apply to become a FDA-approved accreditation
body. The second part established
minimum standards to which a mammography facility must adhere.38
x900.3 of the regulation lays out specic procedures by which an entity can
become
accredited. Most importantly, the entity's application submitted to the FDA
must discuss the applicant's accreditation review and decision-making process.
The following section (x900.4) delineates certain codes of conduct and respon-
sibilities to which the accreditation body must
adhere. The FDA is given the authority to annually evaluate the perfor-
mance of the accreditation
42 U.S.C. 263(b). It is estimated that the FDA will spend about $26 million
in scal year 1997 to implement the act. See Hearings, supra note I.
~ Fran Jordan, Quality Mammograms, WASHINGTON POST,
Jan. 17, 1995, (Health section) at 17.
36See Clintons Use Radio to Urge Women to Get Mammograms; New Rules
are Announced On Breast-Cancer
Testing, BALTIMORE SUN, Oct. 26, 1997, at A3.
~~ Implementation is set forth in 21 C.F.R. x 900 et seq. (1997). 385ee2l
C.F.R. x900.1.
10body.39 As of 1995, there were four approved accreditation bodies: the ACR,
Iowa, California, and Arkansas.40
The rules governing quality standards can be divided into three specic areas:
personnel, practices, and equipment. All mammography facilities must obtain a
certicate issued by the FDA to operate lawfully in the U.S.4' To receive a cer-
ticate, trhe facility must demonstrate that it is accredited by an approved body,
meets the quality standards for equipment, personnel, procedures, and quality
control practices, and have a survey by a quakied medical physicist.42 x900.12
lists the quality standards applicable to pesonnel,equipment, medical records,
and quality assurance. Interpreting physicians, radiologic technologists, and
medical physicists all must have adequate schooling and experience.43 In ad-
dition, the equipment used muist be specically designed for mammography.44
Facilities also need to prepare written reports of the results of each mammog-
raphy examination performed.45 And nally, mammography facilities will be
required to set up quality assurance programs - to ensure that mammograms
are clear and to properly follow up cases.46 In order to enforce these rules, the
FDA (or an authorized inspector)
~ See 21 C.F.R. x900.5.
40 Florence Houn et al., The Mammography Quality Standard~Act of 1992:
History and Process, 50 FooD &
DRUG L.J. 485, 488-89 (1995).
41 See 21 C.F.R. x900.11.
42 See Cocea, supra note 32, at 331
~' See 21 C.F.R. x900.12(a).
~~2l C.F.R. x900.12(b).
435ee 21 C.F.R. x900.12(c).
465ee 21 C.F.R. x900.12(d-f).
11will annually inspect the facilities. The FDA can suspend or revoke a facil-
ity's certicate is it nds that the facility has violated these rules.47 Facilities
had until October 1994 to cpmply with the regulations.
The government has taken the MQSA and its rules very seriously. At its
inception, a government 1-800 hotline telephone number was set up to provide
the names and locations of certied facilities to interested women.48 And the
FDA has even published a publication to help mammography facilities comply
with the requirements of MQSA.49
There were high hopes when the standards were rst passed. Others feared
that small facilities and businesses would be forced to close due to the new
rules.50 The success of the standards seemed to be apparent in the years after
the law was passed. In a very inuential report, the General Accounting Oce
released a study that indicated that the program was a success.5' According to
this report, about four percent of the 10,000 - 11,000 clinics closed rather than
comply with the new rules, and in 95% of those situations another clinic was
within 25
475ee21 C.F.R. x900.14.
~ See Mammogram Hot Line Starts Monday, CHICAGO TRIBUNE,
May 14, 1995, 13.
49
Mammography Matters is a quarterly publication of the Division of Mam-
mography Quality and Radiation Programs, Center for Devices and Radiological
Health.
so
For some additional detailed information, refer to Economic Impact Analysis
of Regulations Under the Mammography Quality Standards Act of 1992 (Oct.
7, 1997), available in
http://www.fda.gov/cdihiecimana. html.
~ Senator Nancy Kassebaum had requested the report in response
to concerns that the FDA rules would put many
clinics out of business and would cost too much. tinder Examination, 12
MED. MALPRACTICE L. & STRATEGY 8 (1995). The GAO report was
released in November of 1995,
12miles.52 Furthermore, although 3500 of the facilities that were investigated
failed to comply with one of the rules, most of them passed on subsequent
inspections.53
After this report was released, everyone viewed the law as a success: We have
delivered to American women better quality mammograms and we have ensured
that no matter whether a woman lives in a big city or a small town, she has access
to this lifesaving service, Donna Shalala, the Secretary of Health and Human
Services, stated.54 There have been some people who have felt otherwise { the
report also states that one-third of the facilities originally certied failed the
subsequent investigation.55 As of June 1995, 1,843 facilities had been inspected.
601 facilities had violations, and 119 of these were serious violations - usually
involving unqualied personnel.56 In the latest GAO report, the agency found
that although some problem areas do exist, overall there is growing compliance
with the mammography standards.57
52 See Under Examination, 13 MED. MAI.PRACTICE L. & STRATEGY
8 (1995).
535ee id
~ US Reports a Healthier Mammogram Picture, WASHINGTON
POST, Nov. 2, 1995, at A3. The report was also used for larger, political
reasons. Representative Dingell seized the report as evidence that Congress
should be cautious in heeding calls by FDA critics to revamp - or even privatize
- the agency. US Reports a Healthier Mammogram Picture, WASHINGTON
POST, Nov. 2, 1995, at A3.
55
See Rich Weiss, Mammography Centers Flunking Inspections, WASHING-
TON POST, Nov. 28, 1995, at 5 (Health
section).
56 See id
'~ See U.S. General Accounting Oce, Report to Congressional Committees,
FDA's Mammography Inspections:
While Some Problems Need Attention, Facility Compliance Is Growing,
GAO/HEHS-97-25 (Jan. 1997). GAO found the following problems: more
consistent reporting is needed, the procedures for assessing image quality need
strengthening, and the enforcement process does not ensure timely correction
of deciencies. See id.
13IV. PROBLEMATIC ISSUES
Although regulation of mammography has largely proved to be benecial, some
problems still remain. In enforcing the MQSA, the FDA faced a (all too famil-
iar) problem of implementation. With limited resources and labor, the FDA
was required to inspect and certify thousands of facilities. At the time, FDA
Commissioner David Kessler was optimistic: It is an all-out eort. I have no
doubt the goal is achievable.58 To help achieve its goal, the FDA invited the
help of other entities. The FDA has relied on its decades-long alliance with
state departments.59 The FDA does do some of its own investigations, how-
ever it primarily trains and provides technical expertise to state inspectors. In
addition, the standards adopted under the MQSA were very similar to the vol-
untary accreditation standards of the American College of Radiology in the
1980s. Because nearly 60% of the facilities adhered to those standards, the
FDA's undertaking seemed less daunting.
A further interesting problem is how the issue of scientic certainty is dealt
with in the regulation of mammography. To date, the FDA has not issued
any guidelines recommending who should take annual mammograms or when
women should start getting mammograms. The FDA has (wisely?) stayed
out of this debate. The problem is simple: when should women start having
mammograms? The solution is far from clear. The National Cancer Institute
(NCI) and the American Cancer Society have been debating the issue for some
time. Initially, the NCI recommended that women start having mammograms
every year or two at age 40. However, around 1993 it changed its position,
stating that women under 50 should look at all the facts and
~ Schwartz, supra note 13.
~ John Henkel, FDA, States Collaborate For Sa~ty's Sake, 30 FDA
CONSUMER 27 (1996).
14decide for themselves. This new position conicts with the views held both
by the American Cancer Society and the American Medical Association.60
This problem is indicative of the inevitable uncertainty of science. Thus
far there is no way to prove denitely that women under 50 should or should
not have annual mammograms. Recommendations are, at best, made out of
educated guesses. Further complicating matters, there is some debate regarding
the safety of mammograms and their eectiveness in detecting cancer in young
women.61 And in a telling policy choice, the FDA has decided to not address
the (real) issue.
A nal point to mention is the amazing coverage and attention mammogra-
phy has received recently. As we all know, the FDA has a limited budget. De-
voting resources to one problem siphons funds away from other worthy causes.
Yet, the FDA has decided that mammography in particular, and breasts in
general, should be a priority item. Even the Clinton administration addressed
the issue as part of its focus on women and health. The broad regulation of
mammography, together with the immense attention given to breast implants,
suggests that the FDA just might be breast obsessed. Has pressure from the
public and from women's groups forced the FDA to make choices it normally
would have shied away from? Or is the FDA simply responding to a killer dis-
ease that has struck down many women and that can be preventable/treatable
if caught early enough?
60 See John C. Goodman, Choice Not Qered]br Mammograms, WALL
STREET JOURNAL, Feb. 3, 1997, at A14;
American Cancer Society, Workshop on Guidelines for Breast Cancer Detec-
tion, Mar. 7-9, 1997, available in
http://www.cancer.org/mammog. html.
61 The link between mammograms and the potential adverse eects of radi-
ation exposure is still being studied and
debated.
15